MediciNova, Inc. (MNOV)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.1500 |
| Open | 2.1500 |
| Bid | 2.1500 x 900 |
| Ask | 2.1600 x 1100 |
| Day's Range | 2.1500 - 2.1900 |
| 52 Week Range | 1.8900 - 3.1800 |
| Volume | |
| Avg. Volume | 26,338 |
| Market Cap | 105.94M |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3120 |
| Earnings Date | May 10, 2023 - May 15, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
LA JOLLA, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to repurpose MN-166 (ibudilast)
- Zacks Small Cap Research
MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update GBM Trial Fully Enrolled On January 12, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced that the Phase 2 trial of MN-166 (ibudilast) in combination with temozolomide (TMZ) for the treatment of glioblastoma (GBM) is fully enrolled ( NCT03782415 ). This is a two-part trial taking place at Dana-Farber Cancer Institute;
